Analysts forecast blockbuster sales for LEO Pharma's tralokinumab by 2027

23 December 2019

Danish dermatology specialist LEO Pharma recently announced that its anti-interleukin-13 (IL-13) biologic therapy tralokinumab, which is in development for the treatment of moderate-to-severe atopic dermatitis, met all its primary and secondary endpoints across three pivotal Phase III studies as part of the company’s ECZTRA trial series.

LEO Pharma is likely to file for approval in 2020, and tralokinumab is expected to be the first biologic treatment in the atopic dermatitis space to challenge Sanofi (Euronext: SAN) and Regeneron’s (Nasdaq: REGN) Dupixent (dupilumab), which quickly solidified its place as the gold standard of therapy since its approval in the US in 2017. LEO acquired rights to tralokinumab from AstraZeneca (LSE: AZN) in 2016.

Tralokinumab forecast to have $1.6 billion sales in 2027

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK